Search

Tackling diabetic retinopathy globally through the VISION 2020 LINKS Diabetic Retinopathy Network

It is abundantly clear that the burden of diabetes is rapidly increasing, as there are now 415 million adults with diabetes in the world, with a projected rise to 642 million by 2040 [1]. This equates to 1 in 10...

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

Surgical options for the treatment of hyperopia

The modern refractive surgeon has a variety of options available to treat patients with hyperopia who wish to be independent of spectacles and contact lenses. Unlike in low myopia where presbyopic patients may have the ability to see well for...

PACK-crosslinking for infectious keratitis

Corneal cross-linking with riboflavin and UV-A light (CXL) is a technology that has been initially developed to treat corneal ectatic disorders [1]. Its effect in stabilising diseases such as keratoconus was reported in numerous trials with excellent long-term outcomes and...

Retinal prosthetics: science fiction or a vision for the future?

“Is it a fact – or have I dreamt it – that, by means of electricity, the world of matter has become a great nerve, vibrating thousands of miles in a breathless point of time?” – Nathaniel Hawthorne, The House...

FAQs about cerebral visual impairment (CVI): identifying and helping those affected

Cerebral visual impairment is common in both adults and children, yet the diagnosis can easily be missed unless one is tuned into the presenting features. This article provides a succinct introduction to this important topic. What is vision? Vision is...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

The ROP Network: a south-south collaboration to improve care for premature babies

Retinopathy of prematurity (ROP) is a disorder of the immature preterm retina and a leading cause of preventable, irreversible blindness in children. There are 15 million preterm births annually, and over 32,000 neonates became blind from ROP in 2010 [1]....

Glaucoma: 30 years on

Back in 1993, the late and great Barry Cullen FRCS (Cavan born, Dublin trained), the first editor of Eye News, asked me to write an article about the current treatment of chronic open angle glaucoma (COAG). At the time I...